Big Cypress Acquisition Corp :Sab Biotherapeutics To List On Nasdaq Through Merger With Big Cypress Acquisition Corp., Advancing Unique Human Antibody Platform With Demonstrated Utility In Immunotherapy And Rapid Response To Emerging Diseases.Sab Biotherapeutics - Upon Merger Closing, Combined Company Is Expected To Be Listed On Nasdaq.Sab Biotherapeutics - Upon Closing Of Proposed Deal, Combined Co Will Operate As Sab Biotherapeutics,Will Continue To Operate Under Sab Management Team.Sab Biotherapeutics - Upon Closing Of Proposed Deal, Big Cypress Acquisition Corp.'S Samuel J. Reich & Jeffrey G. Spragens To Join Co'S Board.Sab Biotherapeutics - Sab Co-Founder, Current Executive Chairman, Edward Hamilton, Plans To Transition To Board Observer Role While Remaining Active In Co.Sab Biotherapeutics - Proposed Transaction Implies An Enterprise Value For Sab, On A Post-Merger Basis, Of About $325 Million.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。